Logo

Menagen Signs a Commercialization Agreement with CKD for Biosimilar Darbepotein Alfa

Share this
Menagen Signs a Commercialization Agreement with CKD for Biosimilar Darbepotein Alfa

Menagen Signs a Commercialization Agreement with CKD for Biosimilar Darbepotein Alfa

Shots:

  • The companies collaborated to commercialize the first biosimilar Darbepoetin alpha in the GCC market for the treatment of anemia associated with chronic renal failure. The CKD biosimilar is currently approved in South Korea
  • The collaboration with CKD helps to build the biosimilar footprint in the Middle East and Africa markets to reach more people living with severe chronic diseases
  • Menagen focuses to provide broad access to patients with unmet medical needs by utilizing its local expertise and capabilities and focus on various niche therapeutic products

  Ref: Business Wire | Image: Business Wire

Click here to­ read the full press release 

Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions